NCT06598202View on ClinicalTrials.gov

Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop

Exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop (administered once daily, twice a week, for a total of two weeks, based on the recommended dose during the dose-escalation phase).

DRUG

a placebo of exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop

Exosomes placebo

Trial Locations (1)

100053

RECRUITING

Xuanwu Hospital ,Capital Medical University, Beijing

All Listed Sponsors
collaborator

Shengqi Medical Technology (Guangzhou) Co., Ltd.

UNKNOWN

collaborator

Viyun (Xiamen) Biomedical Research Institute Co., Ltd.

UNKNOWN

lead

Xuanwu Hospital, Beijing

OTHER